

# AMI KOTHARI, MD

9000 WAUKEGAN ROAD, MORTON GROVE, IL 60053  
(847) 375 – 3000

## EXPERIENCE

---

**Illinois Bone and Joint Institute, LLC**  
Rheumatologist

**Morton Grove, IL**  
September 2009 to Present

## MEDICAL TRAINING

---

**Northwestern University**  
*Rheumatology Fellowship (3-year Program)*

**Chicago, IL**  
2006 to 2009

**University of Illinois at Chicago**  
*Internship 2003*  
*Internal Medicine Residency 2004-2006*

**Chicago, IL**  
2003 to 2006

## EDUCATION

---

**University of Illinois at Chicago**  
*College of Medicine*  
▪ Recipient of Doctor of Medicine in May, 2003

**Chicago, IL**  
1999 to 2003

**University of Illinois at Chicago**  
*College of Liberal Arts and Sciences*  
▪ Recipient of Bachelor of Science in Biological Sciences with Highest Honors in May, 1999  
▪ Minor in Chemistry  
▪ Honors College  
▪ Guaranteed Professional Program Admissions

**Chicago, IL**  
1996 to 1999

## LICENSES & CERTIFICATIONS

---

- Board Certified in Rheumatology
- Board Certified in Internal Medicine in August, 2007
- Passed USMLE Step 3 in June, 2005
- Passed USMLE Step 2 in August, 2002
- Passed USMLE Step 1 in June, 2001

## RESEARCH EXPERIENCE

---

**Northwestern University**  
*Department of Rheumatology*

**Chicago, IL**  
June 2007 to June 2009

- Clinical research with Dr. Leena Sharma in Osteoarthritis
  - Within-Region Analysis of the Relationship of Bone and Cartilage Lesions in Knee Osteoarthritis

**Northwestern University**  
*Department of Rheumatology*

**Chicago, IL**  
September, 2004

- Clinical research with Dr. H.J. Chang
  - Joint Replacement Surgery: Social Support, Ethnicity, and Gender Patterns in Decision Making

# AMI KOTHARI, MD

9000 WAUKEGAN ROAD, MORTON GROVE, IL 60053  
(847) 375 – 3000

## PRESENTATIONS

---

**Northwestern University** **Chicago, IL**  
*Department of Rheumatology* October 18, 2007  
Rheumatology Grand Rounds  
Whipple's Disease: A Review

**Northwestern University** **Chicago, IL**  
*Department of Rheumatology* March 01, 2007  
Rheumatology Grand Rounds  
Henoch-Schonlein Purpura: Clinical Case and Review

**Northwestern University** **Chicago, IL**  
*Department of Rheumatology* April 28, 2008  
MCRC Conference  
The Sequence of Bone and Cartilage Lesions in Knee Osteoarthritis

**Chicago Rheumatology Fellows Meeting** **Chicago, IL**  
Pneumococcal Septic Arthritis December 10, 2008

### Northwestern Medicine Fellows Research Conference Series

**Chicago, IL**  
The Within-Subregion Relationship between Bone Marrow Lesions and  
Cartilage Loss in Knee Osteoarthritis January 20, 2009

## COMMITTEES

---

**Illinois Bone and Joint Institute** **Morton Grove, IL**  
*Practice Management Committee Member-Morton Grove Division* 2015 - Present

## ACADEMIC HONORS

---

- *Phi Eta Sigma* National Honor Society
- *Phi Kappa Phi* Honor Society
- Golden Key National Honors Society

## PROFESSIONAL AFFILIATIONS

---

- American College of Rheumatology
- International Society of Clinical Densitometry

## PUBLICATIONS

---

Abstracts:

- **Within-Region Analysis of the Relationship of Bone and Cartilage Lesions in Knee Osteoarthritis** Ami Kothari<sup>1</sup>, September Cahue<sup>1</sup>, Ali Guermazi<sup>2</sup>, Jing Song<sup>1</sup>, Dorothy Dunlop<sup>1</sup>, Meredith Marshall<sup>1</sup>, Leena Sharma<sup>1</sup>. <sup>1</sup>Northwestern University, Chicago, IL; <sup>2</sup>Boston University, Boston, MA  
Presented 10/26/08 at the American College of Rheumatology Conference in San Francisco Poster Session

# AMI KOTHARI, MD

9000 WAUKEGAN ROAD, MORTON GROVE, IL 60053  
(847) 375 – 3000

## RESEARCH ACTIVITIES

---

### Sub-Investigator:

- 999RA002: Biomarkers of Anti-TNF- $\alpha$  Therapy Efficiency in Rheumatoid Arthritis to Define Unresponsive Patients. Funded by Crescendo Bioscience. 2012 – Ongoing
- CAIN457F2309: A randomized, double-blind, placebo- and active-controlled study of secukinumab to demonstrate the efficacy at 24 weeks and to assess the safety, tolerability and long-term efficacy up to 1 year in patients with active rheumatoid arthritis who have an inadequate response to anti-TNF $\alpha$  agents. Funded by Novartis. 2011 – Ongoing
- H9B-MC-BCDP: A phase 3b, multicenter, open-label study to evaluate the long-term safety and efficacy of LY2127399 in patients with rheumatoid arthritis (RA). Funded by Eli Lilly. 2011 – Ongoing
- A3921129: A randomized, double-blind, placebo-controlled phase 2 study to assess the immune response following administration of influenza and pneumococcal vaccines to subjects with rheumatoid arthritis receiving CP-690,550 or placebo CP-690,550 with and without background methotrexate. Funded by Pfizer. 2011 – Ongoing
- 10-OA-004: An open-label, safety extension study of repeat dosing with intra-articular bone morphogenetic protein (BMP-7) in subjects with osteoarthritis (OA) of the knee. Funded by Stryker Biotech. 2011 – Ongoing
- H9B-MC-BCDO: A phase 3, multi-center, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of LY2127399 in patients with rheumatoid arthritis (RA) with or without background disease-modifying anti-rheumatic drug (DMARD) therapy. Funded by Eli Lilly. 2010 – Ongoing
- WA22762: A randomized, double-blind, parallel group study of the safety and effect on clinical outcome of tocilizumab SC versus tocilizumab IV, in combination with traditional disease modifying anti-rheumatoid arthritis drugs (DMARDs), in patients with moderate to severe active rheumatoid arthritis. Funded by Roche. 2010 – Ongoing
- 09-OA-002: A phase 2, double-blind, randomized, placebo-controlled, proof of concept, dose-finding study of intra-articular bone morphogenetic protein (BMP-7) in subjects with osteoarthritis (OA) of the knee. Funded by Stryker Biotech. 2010 – 2011
- WA19926: A multi-center, randomized, double-blind, parallel group study of the safety, remission and prevention of structural joint damage during treatment with Tocilizumab (CZ), as a monotherapy and in combination with methotrexate (MTX), versus methotrexate in patients with early, moderate to severe early rheumatoid arthritis (RA). Funded by Roche. 2009 – Ongoing
- HZ-CA-401: Open-label safety study of HZT-501 in patients who require long-term daily non-steroidal anti-inflammatory drug treatment. Funded by Horizon Therapeutics. 2009 – 2011
- A4091016: A phase 3, multi-center, randomized, long-term study of the safety of Tanezumab in patients with osteoarthritis of the knee or hip. Funded by Pfizer. 2009 – 2011
- F1J-MC-HMGP: Duloxetine 60 mg once daily versus placebo in the treatment of patients with osteoarthritis knee pain. Funded by Eli Lilly. 2009 – 2010
- ML 22533/B: An open-label, randomized study to evaluate the safety, tolerability and efficacy of tocilizumab (TCZ) monotherapy or TCZ in combination with non-biologic disease modifying anti-rheumatic drugs (DMARDs) in patients with active rheumatoid arthritis who have an inadequate response to current non-biologic or biologic DMARDs. Funded by Roche. 2009 – 2011
- C87084: A phase 3b, multi-center open-label, follow-up study to evaluate the safety and efficacy of certolizumab pegol administered concomitantly with methotrexate in patients with active rheumatoid arthritis who participated in C87077. Funded by UCB. 2009 – 2011

# AMI KOTHARI, MD

9000 WAUKEGAN ROAD, MORTON GROVE, IL 60053  
(847) 375 – 3000

- A4091015: A phase 3 randomized, double-blind placebo and Naproxen-controlled multi-center study of the analgesic efficacy and safety of Tanezumab in patients with osteoarthritis of the knee. Funded by Pfizer. 2009 – 2010
- A3921044: A phase 3 randomized, double-blind, placebo-controlled study of the efficacy and safety of 2 doses of CP-690,550 in patients with active rheumatoid arthritis on background methotrexate. Funded by Pfizer. 2009 – Ongoing
- ACT 4562g: A phase 2, randomized, double-blind, parallel group study to evaluate the efficacy and safety of ocrelizumab in combination with methotrexate compared with Infliximab plus methotrexate in patients with active rheumatoid arthritis currently responding inadequately to Etanercept or Adalimumab. Funded by Genentech. 2009 – 2011
- C87077: Evaluation of the safety and efficacy of an Certolizumab Pegol-administered concomitantly with a stable-dose methotrexate in patients with active rheumatoid arthritis (RA). Funded by UCB. 2007 – 2011
- A3921024: A long-term, open-label follow-up study of Tasocitinib (CP-690,550) for treatment of rheumatoid arthritis. Funded by Pfizer. 2007 – Ongoing
- WA20495/ACT3986g: A randomized, double-blind, parallel group, international study to evaluate the safety and efficacy of ocrelizumab compared to placebo in patients with active rheumatoid arthritis who have an inadequate response to at least one anti-TNF therapy. Funded by Genentech. 2007 – 2011
- WA20494/ACT3985g: A randomized, double-blind, parallel group, international study to evaluate the safety and efficacy of ocrelizumab compared to placebo in patients with active rheumatoid arthritis continuing methotrexate treatment. Funded by Genentech. 2006 – 2011
- WA 18696: A long-term extension study of safety during treatment with tocilizumab (MRA) in patients completing treatment in MRA core studies. Funded by Hoffman-La Roche. 2006 – Ongoing